Amorphical Ltd.

ACTIVE

Israelwww.amorphical.comPrivateEstablished: 2004-01-01

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2004

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

66.7%

Not Applicable

22.2%

Phase 2

11.1%

Trial Status Distribution

Active, not recruiting

11.1%

Completed

22.2%

Terminated

44.4%

Withdrawn

22.2%

Clinical Trials

Trials sponsored by this organization (9)

Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults

Phase 2

Active, not recruiting

interventional

Dec 202462 participants

Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC

Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients.

Phase 1

Completed

interventional

Feb 202166 participants

The Effect of Amorphous Calcium Carbonate (ACC) Treatment on Function and Welfare in Late-stage Solid Cancer Subjects

Phase 1

Terminated

interventional

Jul 201811 participants

Improving Function,Welfare of Late-stage Cancer Subjects by ACC

Phase 1

Terminated

interventional

Jun 201710 participants

A Study Comparing the Effect of Amorphous Calcium Carbonate (ACC) on Healing Time of Distal Radius Fractures

Phase 1

Terminated

interventional

Jun 201315 participants

A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients

Phase 1

Completed

interventional

Apr 201310 participants

A Single Arm Study Comparing ACC Supplement to CCS in Management of Hypoparathyroidism

Not Applicable

Terminated

interventional

Apr 201310 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations